A Pilot Trial to Test the Feasibility of Prolonged Fasting and Ketogenic Diet in Relapsing-remitting Multiple Sclerosis
A Pilot Trial to Test the Feasibility of Prolonged Fasting and Ketogenic Diet in Relapsing-remitting Multiple Sclerosis
It is well accepted that nutrition as an environmental factor is involved in the pathogenesis
 of multiple sclerosis. But is there a role for prolonged fasting and ketogenic low glycemic
 load treatment to alter the course of multiple sclerosis (MS)? The investigators think yes
 there is. Primarily the investigators want to detect if these diets are feasible for MS
 patients. Therefore the investigators examine the impact of this dietary intervention on the
 health related quality of life for individuals after 7 days, 3 months and 6 months in compare
 to baseline. Secondarily the investigators focus on endocrinological and immunological
 changes after 7 days, 3 months and 6 months in compare to baseline.
In this controlled randomised pilot study the patients are allocated to 1. a ketogenic low
 glycemic load treatment from the outset of the study for 24 weeks or 2. enhance their regular
 diet with an initial 7-day fasting followed by a Mediterranean diet pattern until the study
 end or 3. stay on their regular diet (control group) from the outset of the study for 24
 weeks. The investigators will then assess the differences between the groups.
Inclusion Criteria:

 -  Relapsing remitting MS

 -  Stable immunomodulatory treatment or no treatment at least 6 months prior to inclusion

 -  Expanded disability status scale < 7

 -  Body mass index (BMI) > or = 18,5 OR BMI > or = 45 with no risk factors

 -  Not pregnant or breast-feeding

 -  No serious mental health illness such as dementia or schizophrenia;

 -  No use of a weight loss therapy in the month prior to screening.

 Exclusion Criteria:

 -  Start or changes if immunomodulatory treatment < 7 months prior to screening

 -  SPMS or PPMS

 -  Relapse or corticosteroid use < 30 days prior to screening

 -  Diabetes or any metabolic defects

 -  Bulimia

 -  Anorexia

 -  Drug abuse